"The GvHD is a strategical error in my opinion, but nothing I...

"The GvHD is a strategical error in my opinion, but nothing I say going to change that. The largest partnered Phase III Knee OA trial of its kind will dictate this company's future"

I see your point but disagree. There is good evidence that MSCs are efficacious in treating GvHD given their excellent immunomodulatory features - the Mesoblast trial data demonstrates this. The issue has been that the mechanism of action indicated in pre-clinical data hasn't matched what occurred in clinical trials. The FDA are clear that this second point can be ignored and the product commercialised from good efficacy alone...as long as the clinical trial is well-controlled. This is where Cynata are differentiating themselves from Mesoblast. By targeting patients earlier in the treatment phase, and administering CYP-001 in conjunction with the standard of care, there is not an obvious disadvantage for a patient to enter the trial. Conversely, Mesoblast are basically providing a 'Last-line of defence' option for patients. Admirable, and again, the results were good. However to run a randomised, controlled, clinical trial at this stage would be very difficult given the dire outlook for those who got the placebo.

This post isn't to restart the CYP v MSB wars. It's to point out the positives Cynata can take from MSB's forays into the US with Rem-L, and how Cynata's approach makes it more likely to tick the boxes required for commercialisation.

Regarding Knee OA - you may well be right. Again, as you pointed out, there are strong results out of South Korea demonstrating MSCs are efficacious in treating Knee osteoarthritis. But I feel like this is more like a (giant) cherry on top of the sundae if we get good results and more importantly a commercial partner. The 'average' investor understands that 'stem cells' and 'gvhd' are connected in some way, given the enormous amount written about Mesoblast and their trials and tribulations. Therefore I feel that demonstrating progress with this will create momentum to push the value of Cynata back up in a more linear fashion.